You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

Details for Patent: 8,524,779


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,524,779 protect, and when does it expire?

Patent 8,524,779 protects VERKAZIA and is included in one NDA.

This patent has forty-four patent family members in eighteen countries.

Summary for Patent: 8,524,779
Title:Emulsion compositions containing quaternary ammonium compounds
Abstract: Composition containing quaternary ammonium compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, the composition including at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions are also disclosed.
Inventor(s): Rabinovich-Guilatti; Laura (Kadima, IL), Lambert; Gregory (Chatenay Malabry, FR), Lallemand; Frederic (Fresnes, FR), Philips; Betty (Antony, FR)
Assignee: Novagali Pharma SA (Evry, FR)
Application Number:13/096,512
Patent Claim Types:
see list of patent claims
Composition;

Drugs Protected by US Patent 8,524,779

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Harrow Eye VERKAZIA cyclosporine EMULSION;OPHTHALMIC 214965-001 Jun 23, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,524,779

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06291236.5Jul 28, 2006
07112097.6Jul 9, 2007
PCT/IB2007/053441Jul 10, 2007

International Family Members for US Patent 8,524,779

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2049079 ⤷  Sign Up PA2017003 Lithuania ⤷  Sign Up
European Patent Office 2049079 ⤷  Sign Up LUC00006 Luxembourg ⤷  Sign Up
European Patent Office 2049079 ⤷  Sign Up PA2017003,C2049079 Lithuania ⤷  Sign Up
Australia 2007278141 ⤷  Sign Up
Canada 2659322 ⤷  Sign Up
China 101534791 ⤷  Sign Up
Cyprus 1114457 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.